Roche develops new test kits for COVID-19 Omicron variant


ZURICH, Dec 3 (Reuters) - Roche's ROG.S newly acquired subsidiary TIB Molbiol has developed three new tests kits to detect mutations present in the new COVID-19 Omicron variant, Roche said on Friday.

"The teams at TIB Molbiol have worked around the clock since the new variant emerged, and today we are able to offer a test that can specifically identify the novel B.1.1.529 Omicron SARS-CoV-2 variant to help better understand its spread and behaviour," Thomas Schinecker, head of Roche Diagnostics, said in a statement.

Roche acquired Berlin-based TIB Molbiol on Dec. 1 to expand its PCR-test portfolio to combat new infectious diseases.

(Reporting by Brenna Hughes Neghaiwi Editing by Paul Carrel)

((; +41 58 306 77 35;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.